128 related articles for article (PubMed ID: 24361684)
1. The tyrosine kinase inhibitor Dasatinib blocks in-vitro HIV-1 production by primary CD4+ T cells from HIV-1 infected patients.
Pogliaghi M; Papagno L; Lambert S; Calin R; Calvez V; Katlama C; Autran B
AIDS; 2014 Jan; 28(2):278-81. PubMed ID: 24361684
[TBL] [Abstract][Full Text] [Related]
2. Dasatinib inhibits HIV-1 replication through the interference of SAMHD1 phosphorylation in CD4+ T cells.
Bermejo M; López-Huertas MR; García-Pérez J; Climent N; Descours B; Ambrosioni J; Mateos E; Rodríguez-Mora S; Rus-Bercial L; Benkirane M; Miró JM; Plana M; Alcamí J; Coiras M
Biochem Pharmacol; 2016 Apr; 106():30-45. PubMed ID: 26851491
[TBL] [Abstract][Full Text] [Related]
3. [Viral dynamics in the course of HIV-1 infection: pathogenetic features and new therapeutic prospects].
Marcello A; Giacca M
Pathologica; 2000 Aug; 92(4):291-3. PubMed ID: 11029891
[No Abstract] [Full Text] [Related]
4. Analysis of protein kinase C theta inhibitors for the control of HIV-1 replication in human CD4+ T cells reveals an effect on retrotranscription in addition to viral transcription.
Bermejo M; López-Huertas MR; Hedgpeth J; Mateos E; Rodríguez-Mora S; Maleno MJ; Plana M; Swindle J; Alcamí J; Coiras M
Biochem Pharmacol; 2015 Apr; 94(4):241-56. PubMed ID: 25732195
[TBL] [Abstract][Full Text] [Related]
5. Reservoirs for HIV-1: mechanisms for viral persistence in the presence of antiviral immune responses and antiretroviral therapy.
Pierson T; McArthur J; Siliciano RF
Annu Rev Immunol; 2000; 18():665-708. PubMed ID: 10837072
[TBL] [Abstract][Full Text] [Related]
6. The search for a cure for persistent HIV reservoirs.
Lafeuillade A; Stevenson M
AIDS Rev; 2011; 13(2):63-6. PubMed ID: 21587339
[TBL] [Abstract][Full Text] [Related]
7. HIV-1 and HAART: a time to cure, a time to kill.
Saag MS; Kilby JM
Nat Med; 1999 Jun; 5(6):609-11. PubMed ID: 10371490
[No Abstract] [Full Text] [Related]
8. Atorvastatin restricts HIV replication in CD4+ T cells by upregulation of p21.
Elahi S; Weiss RH; Merani S
AIDS; 2016 Jan; 30(2):171-83. PubMed ID: 26645604
[TBL] [Abstract][Full Text] [Related]
9. Potential role of tyrosine kinase inhibitors during primary HIV-1 infection.
Ambrosioni J; Coiras M; Alcamí J; Miró JM
Expert Rev Anti Infect Ther; 2017 May; 15(5):421-423. PubMed ID: 28322065
[No Abstract] [Full Text] [Related]
10. Effect of target cell availability on HIV-1 production in vitro.
Schwartz EJ; Neumann AU; Teixeira AV; Bruggeman LA; Rappaport J; Perelson AS; Klotman PE
AIDS; 2002 Feb; 16(3):341-5. PubMed ID: 11834944
[TBL] [Abstract][Full Text] [Related]
11. The development of immune-modulating compounds to disrupt HIV latency.
Remoli AL; Marsili G; Battistini A; Sgarbanti M
Cytokine Growth Factor Rev; 2012; 23(4-5):159-72. PubMed ID: 22766356
[TBL] [Abstract][Full Text] [Related]
12. Novel mechanisms to inhibit HIV reservoir seeding using Jak inhibitors.
Gavegnano C; Brehm JH; Dupuy FP; Talla A; Ribeiro SP; Kulpa DA; Cameron C; Santos S; Hurwitz SJ; Marconi VC; Routy JP; Sabbagh L; Schinazi RF; Sékaly RP
PLoS Pathog; 2017 Dec; 13(12):e1006740. PubMed ID: 29267399
[TBL] [Abstract][Full Text] [Related]
13. Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection.
Chun TW; Carruth L; Finzi D; Shen X; DiGiuseppe JA; Taylor H; Hermankova M; Chadwick K; Margolick J; Quinn TC; Kuo YH; Brookmeyer R; Zeiger MA; Barditch-Crovo P; Siliciano RF
Nature; 1997 May; 387(6629):183-8. PubMed ID: 9144289
[TBL] [Abstract][Full Text] [Related]
14. Barriers to a cure for HIV: new ways to target and eradicate HIV-1 reservoirs.
Katlama C; Deeks SG; Autran B; Martinez-Picado J; van Lunzen J; Rouzioux C; Miller M; Vella S; Schmitz JE; Ahlers J; Richman DD; Sekaly RP
Lancet; 2013 Jun; 381(9883):2109-17. PubMed ID: 23541541
[TBL] [Abstract][Full Text] [Related]
15. HIV-1 viral replication below 50 copies/ml in patients on antiretroviral therapy is not associated with CD8+ T-cell activation.
Steel A; Cox AE; Shamji MH; John L; Nelson M; Henderson DC; Gotch FM; Gazzard BG; Kelleher P
Antivir Ther; 2007; 12(6):971-5. PubMed ID: 17926652
[TBL] [Abstract][Full Text] [Related]
16. Dasatinib protects humanized mice from acute HIV-1 infection.
Salgado M; Martinez-Picado J; Gálvez C; Rodríguez-Mora S; Rivaya B; Urrea V; Mateos E; Alcamí J; Coiras M
Biochem Pharmacol; 2020 Apr; 174():113625. PubMed ID: 31476293
[TBL] [Abstract][Full Text] [Related]
17. Failure to reconstitute CD4+ T-cells despite suppression of HIV replication under HAART.
Aiuti F; Mezzaroma I
AIDS Rev; 2006; 8(2):88-97. PubMed ID: 16848276
[TBL] [Abstract][Full Text] [Related]
18. In vitro induction of HIV-1 replication in resting CD4(+) T cells derived from individuals with undetectable plasma viremia upon stimulation with human T-cell leukemia virus type I.
Moriuchi H; Moriuchi M
Virology; 2000 Dec; 278(2):514-9. PubMed ID: 11118373
[TBL] [Abstract][Full Text] [Related]
19.
Nemeth J; Vongrad V; Metzner KJ; Strouvelle VP; Weber R; Pedrioli P; Aebersold R; Günthard HF; Collins BC
Mol Cell Proteomics; 2017 Apr; 16(4 suppl 1):S108-S123. PubMed ID: 28223351
[TBL] [Abstract][Full Text] [Related]
20. Mechanisms underlying activity of antiretroviral drugs in HIV-1-infected macrophages: new therapeutic strategies.
Aquaro S; Svicher V; Schols D; Pollicita M; Antinori A; Balzarini J; Perno CF
J Leukoc Biol; 2006 Nov; 80(5):1103-10. PubMed ID: 16931601
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
